# Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy

> **NCT05221411** · PHASE4 · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 86 (estimated)

## Conditions studied

- Autoimmune Hepatitis

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT05221411
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-19
- **Primary completion:** 2023-01
- **Final completion:** 2024-01
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221411, "Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05221411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*